"For Glycotope, the approval of CetuGEX, our 2nd antibody in the clinic, represents another important milestone" said Steffen Goletz, CEO & CSO of Glycotope.

"CetuGEX is our first in a series of next generation biotherapeutic products. We expect that the strong advantages in various product aspects we have seen in preclinical studies will manifest in a clear clinical superiority compared to the currently marketed product. In addition, the 2nd cell line of Glycotope’s glycooptimisation platform GlycoExpress based on human cell lines has now been approved, meeting our ambitions for quality and speed." CetuGEX was the second antibody in clinical stage produced in Glycotope’s own GMP facility in Heidelberg.